Floatz logo

Daunorubicin

CRC (Colorectal Cancer)

Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.Phase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the CRC (Colorectal Cancer) cohort.

Asset / SponsorPhaseRating
Shr-1701
Fudan University
Phase 2/3B
Ruxolitinib
Philogen S.p.A.
Phase 2B
Inca33890
Incyte Corporation
Phase 3B
PEGASPARGASE
Biotheus Inc.
Phase 2CCC
pm8002
Biotheus Inc.
Phase 2CCC

View all 19 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →